Etopol 100 Injection contains Etoposide 100 mg, an anticancer medicine widely used in the treatment of various malignancies as part of combination chemotherapy protocols. It helps in slowing or stopping the growth of cancer cells by interfering with DNA replication and cell division processes that are essential for tumor development. The injection is administered under the supervision of oncology specialists and plays an important role in modern cancer treatment programs.

Etoposide belongs to the class of topoisomerase II inhibitors and works by disrupting the DNA repair mechanisms within rapidly dividing cancer cells. This action leads to cancer cell death and helps control the progression of malignant diseases. Its established mechanism of action and broad therapeutic utility have made it an important component of several chemotherapy regimens used in oncology practice worldwide.

The injection is commonly prescribed in the treatment of small cell lung cancer, testicular cancer, lymphoma, leukemia, and certain other solid tumors as determined by an oncology specialist. It is frequently used in combination with other anticancer medicines to enhance treatment effectiveness and improve clinical outcomes. Careful monitoring during therapy is essential to ensure optimal benefits and manage potential treatment-related adverse effects.

With the increasing demand for advanced oncology treatments and specialized cancer care, Etopol 100 Injection holds significant value in the anticancer segment. Its proven clinical efficacy, broad therapeutic applications, and inclusion in multiple chemotherapy protocols contribute to consistent market demand. The product offers strong business potential for retailers and distributors seeking growth opportunities within the expanding oncology pharmaceutical market.

Etopol 100 Injection may cause nausea, vomiting, loss of appetite, hair loss, fatigue, weakness, diarrhea, mouth ulcers, low blood cell counts, and injection site reactions. Bone marrow suppression, increased susceptibility to infections, anemia, bleeding tendencies, and allergic reactions may occur and require close medical monitoring.

Etopol 100 Injection is indicated for the treatment of small cell lung cancer, testicular cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, leukemia, and other malignancies as determined by an oncology specialist. It helps control cancer cell growth and forms part of comprehensive chemotherapy treatment regimens.

This medication should be administered only by qualified healthcare professionals experienced in cancer chemotherapy. Regular monitoring of blood counts, liver function, kidney function, and overall patient condition is essential throughout treatment. Patients should promptly report symptoms such as fever, unusual bleeding, severe fatigue, shortness of breath, or signs of infection. Treatment should be individualized according to the patient's condition and response to therapy.

Store in a cool, dry place below 25°C, protected from direct sunlight and moisture. Keep the vial in its original packaging until use and out of reach of children. Do not use after the expiry date or if the packaging is damaged, opened, or shows signs of deterioration.